ABBVIE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification

Phase 3

Completed

Conditions: Glioblastoma
Gliosarcoma

Interventions: Drug: Temozolomide
Radiation: Radiation
Drug: Depatuxizumab mafodotin
Drug: Placebo for ABT-414

First Posted Date: 2015-10-09

Last Posted Date: 2023-05-11

Lead Sponsor: AbbVie

Target Recruit Count: 691

Registration Number: NCT02573324

Locations: 🇺🇸
Piedmont Hospital /ID# 145892, Atlanta, Georgia, United States
🇺🇸
Emory Midtown Infectious Disease Clinic /ID# 144015, Atlanta, Georgia, United States
🇺🇸
University of Pennsylvania Medical Center - Shadyside /ID# 144159, Pittsburgh, Pennsylvania, United States

and more 209 locations

ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors
Undifferentiated Pleomorphic Sarcoma
Squamous Cell Carcinoma of the Head and Neck
Carcinoma of the Breast

Interventions: Drug: ABBV-085

First Posted Date: 2015-10-01

Last Posted Date: 2019-04-05

Lead Sponsor: AbbVie

Target Recruit Count: 85

Registration Number: NCT02565758

Locations: 🇺🇸
Carolina BioOncology Institute /ID# 148583, Huntersville, North Carolina, United States
🇺🇸
NYU Langone Medical Center /ID# 150786, New York, New York, United States
🇺🇸
Greenville Hospital System /ID# 148652, Greenville, South Carolina, United States

and more 17 locations

RST-001 Phase I/II Trial for Advanced Retinitis Pigmentosa

Phase 1

Completed

Conditions: Advanced Retinitis Pigmentosa

Interventions: Drug: RST-001

First Posted Date: 2015-09-22

Last Posted Date: 2024-11-08

Lead Sponsor: AbbVie

Target Recruit Count: 14

Registration Number: NCT02556736

Locations: 🇺🇸
Retina Foundation of the Southwest, Dallas, Texas, United States
🇺🇸
Duke Eye Center, Durham, North Carolina, United States
🇺🇸
Cincinnati Eye Institute, Cincinnati, Ohio, United States

and more 1 locations

A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)

Phase 3

Completed

Conditions: Advanced Parkinson's Disease

Interventions: Drug: Optimized Medical Treatment
Device: Nasojejunal (NJ) tube
Drug: Levodopa-Carbidopa Intestinal Gel
Device: Percutaneous endoscopic gastrostomy with a jejunal (PEG-J) tube

First Posted Date: 2015-09-15

Last Posted Date: 2023-11-28

Lead Sponsor: AbbVie

Target Recruit Count: 89

Registration Number: NCT02549092

Locations: 🇨🇦
Toronto Western Hospital /ID# 136585, Toronto, Ontario, Canada
🇬🇷
Mediterraneo Hospital /ID# 208042, Glyfada, Greece
🇨🇦
University of Alberta /ID# 136586, Edmonton, Alberta, Canada

and more 35 locations

Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: ABT-450/r/ABT-267
Drug: ABT-333

First Posted Date: 2015-08-28

Last Posted Date: 2015-10-19

Lead Sponsor: AbbVie

Target Recruit Count: 18

Registration Number: NCT02534870

Locations: 🇨🇳
Site Reference ID/Investigator# 137655, Shanghai, China

Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)

Phase 3

Completed

Conditions: Generalized Pustular Psoriasis (GPP)
Adalimumab
Japanese

Interventions: Drug: Adalimumab

First Posted Date: 2015-08-26

Last Posted Date: 2019-01-14

Lead Sponsor: AbbVie

Target Recruit Count: 10

Registration Number: NCT02533375

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABBV-257 in Subjects With Rheumatoid Arthritis

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Biological: ABBV-257
Biological: Placebo

First Posted Date: 2015-08-24

Last Posted Date: 2016-03-03

Lead Sponsor: AbbVie

Target Recruit Count: 8

Registration Number: NCT02531178

Locations: 🇩🇪
Site Reference ID/Investigator# 139394, Berlin, Germany

ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection

Phase 3

Completed

Conditions: Hepatitis C Virus (HCV)

Interventions: Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir
Drug: Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir

First Posted Date: 2015-08-07

Last Posted Date: 2017-10-27

Lead Sponsor: AbbVie

Target Recruit Count: 650

Registration Number: NCT02517515

ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis

Phase 3

Completed

Conditions: Chronic Hepatitis C Virus (HCV)

Interventions: Drug: ABT-450/r/ABT-267
Drug: ABT-333
Drug: ribavirin

First Posted Date: 2015-08-07

Last Posted Date: 2018-10-09

Lead Sponsor: AbbVie

Target Recruit Count: 104

Registration Number: NCT02517528

A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease

Phase 2

Completed

Conditions: Crohn Disease

Interventions: Drug: Risankizumab 600 mg IV
Drug: Risankizumab 180 mg SC

First Posted Date: 2015-07-31

Last Posted Date: 2020-04-24

Lead Sponsor: AbbVie

Target Recruit Count: 65

Registration Number: NCT02513459

Locations: 🇧🇪
AZ-Delta /ID# 154983, Roeselare, Belgium
🇺🇸
MGG Group, Inc.Chevy Chase Clinical Research /ID# 155068, Chevy Chase, Maryland, United States
🇪🇸
Hospital Univ de la Princesa /ID# 155065, Madrid, Spain

and more 25 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy